Research suggests that saffron and its active compounds — particularly crocin and crocetin — may offer protective benefits for eye health across several conditions, including age-related macular degeneration, cataracts, diabetic retinopathy, and glaucoma. The available evidence includes a 2023 narrative review of laboratory, animal, and early clinical data showing antioxidant, anti-inflammatory, and cell-protective effects in retinal tissue; a small 2021 open-label pilot trial in which a multi-ingredient supplement containing saffron extract was associated with meaningful improvements in dry AMD symptoms over 90 days; and a 2025 animal study in which saffron extract reduced cataract severity in cholesterol-fed rabbits. Studies indicate a generally supportive direction across these findings, though the human evidence remains limited to small, short-term trials without robust placebo controls, and most mechanistic insights come from preclinical models that may not fully translate to humans. Larger and more rigorously designed clinical trials are needed before strong conclusions about saffron's role in eye health can be drawn.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Crocin as a vision supplement. | Review | 2023 | Supports | 100 |
| An Open-Label Pilot Study on Macumax Supplementation for Dry-Type Age-Related... | RCT | 2021 | Supports | 95 |
| Saffron's protective role against atherosclerosis-induced cataract progressio... | Other | 2025 | Supports | 90 |
| Development of a UHPLC-MS method to avoid the in-source dissociation interfer... | Other | 2025 | Neutral | 85 |